

Neutropenia Biologic Drug Treatment Market Players Work On Novel Drug Delivery Systems

*The Business Research Company's
Neutropenia Biologic Drug Treatment
Global Market Report 2022 – Market Size,
Trends, And Global Forecast 2022-2026*

LONDON, GREATER LONDON, UK, April 7, 2022 /EINPresswire.com/ -- TBRC's [neutropenia biologic drug treatment market overview](#) shows that


companies are increasingly investing in developing novel drug delivery systems to improve the therapeutic response of the drug and increase its efficacy.

Novel drug delivery systems allow the delivery of a very high dose of drugs directly into the neutrophils, while the systemic dose remains low, thus disallowing side-effects. For instance, in August 2020, Asalyxa Bio announced its formation and seed funding to accelerate ASX-100 into first-in-human trials in 2021. ASX-100 is a novel spherical particle that releases a safe and effective anti-inflammatory agent, salicylic acid, directly to over-reactive immune cells, and is used for treating severe neutrophil-mediated disease.

In September 2020, Gilead Sciences, a US-based biopharmaceutical company launched Immunomedics for \$21 billion. Through this acquisition Gilead will get Trodelvy™ (acituzumab govitecan-hziy), which will alter Gilead's portfolio by adding a first-in-class commercial drug with considerable revenue potential and best-in-class potential. Immunomedics is a US-based biotechnology company that offers neutropenia biologic drug treatment.

Read more on the Global Neutropenia Biologic Drug Treatment Market Report <https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report>

The global neutropenia biologic drug treatment market size is expected to grow from \$10.22 billion in 2021 to \$11.26 billion in 2022 at a compound annual growth rate (CAGR) of 10.2%. The growth in the market is mainly due to the companies resuming their operations and adapting to



the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The neutropenia biologic drug market is expected to reach \$14.78 billion in 2026 at a CAGR of 7.0%.

The rise in the number of cancer cases across the globe is likely to contribute to the [neutropenia biologic drug treatment market growth](#). Due to a growing cancer incidence and an increase in the number of people opting for chemotherapy, there has been an increasing incidence in the number of people suffering from neutropenia. According to the neutropenia biologic drug treatment market forecast, the rise in cancer incidence rate globally is anticipated to boost the demand for the market over the forthcoming years.

Major players covered in the global neutropenia biologic drug treatment industry are Teva Pharmaceutical, Amgen, Sanofi, Mylan, Kyowa Kirin, Baxter International, CVS Health Corp, Novartis, Spectrum Pharmaceuticals, and Partner Therapeutics.

TBRC's global neutropenia biologic drug treatment market analysis report is segmented by drug type into filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, sargramostim, by treatment type into antibiotic drugs, granulocyte-colony-stimulating factor (G-CSF), antifungal drugs, others, by distribution channel into retail pharmacies, hospital pharmacies, online pharmacies.

Neutropenia Biologic Drug Treatment Global Market Report 2022 – By Drug Type (Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim), By Treatment Type (Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a neutropenia biologic drug treatment market overview, forecast neutropenia biologic drug treatment market size and growth for the whole market, neutropenia biologic drug treatment market segments, geographies, neutropenia biologic drug treatment market trends, neutropenia biologic drug treatment market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request for a Sample of the Global Neutropenia Biologic Drug Treatment Market Report <https://www.thebusinessresearchcompany.com/sample.aspx?id=3456&type=smp>

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Biologics Global Market Report 2022 – By Type (Monoclonal Antibodies (MAbs), Therapeutic Proteins, Vaccines), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) –

Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/biologics-global-market-report>

Filgrastim Biosimilars Global Market Report 2022 – By Application (Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Type Of Manufacturing (In-House Manufacturing, Contract Manufacturing Organization) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report>

Pegfilgrastim Biosimilars Global Market Report 2022 – By Application (Chemotherapy Treatment, Transplantation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report>

About [The Business Research Company?](https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx)

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <https://bit.ly/3b7850r>

Twitter: <https://bit.ly/3b1rmjS>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/567749083>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.